期刊： LANCET RESPIRATORY MEDICINE, 2022; 10 (4)
Background Lung cancer is the leading cause of cancer death worldwide. Data on the effectiveness of one-off low-dose CT (LDCT) in reducing lung cancer......
期刊： LANCET RESPIRATORY MEDICINE, 2022; 10 (8)
Background Due to waning immunity and protection against infection with SARS-CoV-2, a third dose of a homologous or heterologous COVID-19 vaccine has ......
期刊： LANCET RESPIRATORY MEDICINE, 2022; 10 (9)
Background With the ongoing COVID-19 pandemic, growing evidence shows that a considerable proportion of people who have recovered from COVID-19 have l......
期刊： LANCET RESPIRATORY MEDICINE, 2022; 10 (8)
Background All currently available SARS-CoV-2 vaccines are administered by intramuscular injection. We aimed to evaluate the safety and immunogenicity......
期刊： LANCET RESPIRATORY MEDICINE, 2021; 9 (3)
Background Immunotherapy combined with chemotherapy has been shown to be efficacious as treatment for advanced non-squamous non-small-cell lung cancer......
期刊： LANCET RESPIRATORY MEDICINE, 2021; 9 (9)
Background Icotinib has provided survival benefits for patients with advanced, epidermal growth factor receptor (EGFR)-mutant non-small-cell lung canc......
期刊： LANCET RESPIRATORY MEDICINE, 2021; 9 (7)
Background The consequences of COVID-19 in those who recover from acute infection requiring hospitalisation have yet to be clearly defined. We aimed t......
期刊： LANCET RESPIRATORY MEDICINE, 2021; 9 (8)
Background Furmonertinib (AST2818) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting both sensit......
期刊： LANCET RESPIRATORY MEDICINE, 2021; 9 (8)
Background Previous studies suggested that the prevalence of chronic respiratory disease in patients hospitalised with COVID-19 was lower than its pre......
期刊： LANCET RESPIRATORY MEDICINE, 2021; 9 (9)
Background Prevention, control, and treatment of respiratory tract cancers are important steps towards achieving target 3.4 of the UN Sustainable Deve......
期刊： LANCET RESPIRATORY MEDICINE, 2021; 9 (2)
Background In mild asthma, as-needed budesonide-formoterol reduces long-term exacerbation risk compared with as-needed short-acting beta(2)-agonist (S......
